Literature DB >> 28479900

Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia.

Ines Derbel1, Asma Ghorbel1,2,3, Férièle Messadi Akrout1,2, Abdelmajid Zahaf4.   

Abstract

BACKGROUND: Illicit use of high dosage buprenorphine has been well documented in several countries, including Tunisia.
OBJECTIVES: The aim of this survey is to assess the buprenorphine withdrawal syndrome time course, and how it may be affected by the population characteristics among subjects admitted to a rehabilitation center in Tunisia.
METHODS: A prospective research has permitted study of the socio-demographic characteristics and assessment of buprenorphine withdrawal syndrome among 32 subjects admitted for buprenorphine dependence by using the clinical opiate withdrawal scale. An ANOVA was conducted to examine the effect of different factors on the withdrawal scores.
RESULTS: 32 subjects were included. Among them 30 were males, 27 had been injecting buprenorphine, 16 were poly-drug abusers and 2 had a history of mental disorders. Buprenorphine withdrawal syndrome was of a mild intensity and had a delayed onset. Withdrawal mean scores varied between 0 and 9, and maximum values were reached at day 21. These scores varied significantly over time (p<0,001). The sex v time interaction and the mode of consumption of buprenorphine had significant effects on the withdrawal scores (p<0,001). The poly-drug consumption and the history of mental disorders did not have any significant effect on the withdrawal scores.
CONCLUSION: This study has permitted description of buprenorphine withdrawal syndrome among patients going through a detoxification treatment at a rehabilitation center. Understanding this syndrome would help elaborate effective and suitable buprenorphine dependence management plans.

Entities:  

Keywords:  Buprenorphine; dependence; withdrawal

Mesh:

Substances:

Year:  2016        PMID: 28479900      PMCID: PMC5398454          DOI: 10.4314/ahs.v16i4.24

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  29 in total

1.  Differences in severity of heroin dependence by route of administration: the importance of length of heroin use.

Authors:  G Barrio; L De La Fuente; C Lew; L Royuela; M J Bravo; M Torrens
Journal:  Drug Alcohol Depend       Date:  2001-07-01       Impact factor: 4.492

2.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

3.  Biologic Commonalities between Mental Illness and Addiction.

Authors:  Karen J Hartwell; Bryan K Tolliver; Kathleen T Brady
Journal:  Prim psychiatry       Date:  2009-08-01

4.  [Should high-dose buprenorphine be withdrawn from the French market?].

Authors:  B Rolland; A Muyssen; T Danel; O Cottencin
Journal:  Rev Epidemiol Sante Publique       Date:  2013-03-11       Impact factor: 1.019

5.  Buprenorphine.

Authors:  Bethany Foster; Robert Twycross; Mary Mihalyo; Andrew Wilcock
Journal:  J Pain Symptom Manage       Date:  2013-05       Impact factor: 3.612

6.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

7.  Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.

Authors:  Margareeta Häkkinen; Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2011-09-17       Impact factor: 2.953

Review 8.  Benzodiazepines, methadone and buprenorphine: interactions and clinical management.

Authors:  Nicholas Lintzeris; Suzanne Nielsen
Journal:  Am J Addict       Date:  2010 Jan-Feb

9.  Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

Authors:  R Douglas Bruce; Sumathi Govindasamy; Laurie Sylla; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

10.  A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.

Authors:  D Andrew Tompkins; Michael T Smith; Miriam Z Mintzer; Claudia M Campbell; Eric C Strain
Journal:  J Pharmacol Exp Ther       Date:  2013-11-13       Impact factor: 4.030

View more
  3 in total

1.  Child, reproductive, mental health; infections and NCDs in the African environment.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

2.  The Opioid Epidemic in Africa And Its Impact.

Authors:  Ann E Kurth; Peter Cherutich; Rosabelle Conover; Nok Chhun; R Douglas Bruce; Barrot H Lambdin
Journal:  Curr Addict Rep       Date:  2018-10-30

3.  A Novel Maintenance Therapeutic for Opioid Use Disorder.

Authors:  Beth Youngblood; Kevin Li; Donald R Gehlert; Julio C Medina; Neil Schwartz
Journal:  J Pharmacol Exp Ther       Date:  2021-05-19       Impact factor: 4.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.